Sign In

Login

Password

Forgot Password ? Sign Up

Multiple Sklerose (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Multiple Sklerose" in German language version.

refsWebsite
Global rank German rank
147nih.gov
4th place
7th place
134doi.org
2nd place
3rd place
14zdb-katalog.de
123rd place
6th place
10web.archive.org
1st place
1st place
7europa.eu
68th place
29th place
6dgn.org
low place
3,008th place
6akdae.de
low place
1,853rd place
4redirecter.toolforge.org
33rd place
2nd place
3atlasofms.org
low place
low place
2elsevier.com
610th place
521st place
2dmsg.de
low place
low place
2nejm.org
2,374th place
1,391st place
2sagepub.com
731st place
969th place
2aerzteblatt.de
3,043rd place
200th place
2google.de
2,106th place
139th place
2kompetenznetz-multiplesklerose.de
low place
low place
2merckgroup.com
low place
low place
2pharmazeutische-zeitung.de
8,614th place
583rd place
2sanofi.com
low place
low place
2awmf.org
5,401st place
312th place
2fda.gov
447th place
751st place
1who.int
195th place
255th place
1biomedcentral.com
2,747th place
1,415th place
1fu-berlin.de
3,329th place
378th place
1nature.com
234th place
203rd place
1zeit.de
267th place
15th place
1spektrum.de
1,960th place
130th place
1rki.de
4,845th place
310th place
1medical-tribune.de
low place
4,040th place
1uniklinik-freiburg.de
low place
5,446th place
1mpg.de
1,624th place
377th place
1scientificamerican.com
896th place
1,716th place
1vam.ac.uk
2,871st place
4,883rd place
1google.cl
2,768th place
6,858th place
1ucl.ac.uk
1,306th place
2,552nd place
1medscape.com
719th place
1,553rd place
1springer.com
274th place
152nd place
1IABotmemento.invalid
low place
low place
1ectrims-congress.eu
low place
low place
1deutsche-apotheker-zeitung.de
low place
797th place
1reuters.com
49th place
151st place
1aerztezeitung.de
low place
711th place
1multiple-sklerose.com
low place
low place
1informa.com
low place
9,244th place
1amsel.de
low place
low place
1pharmaphorum.com
low place
low place
1handelsblatt.com
1,065th place
65th place
1sciencedirect.com
149th place
298th place
1core.ac.uk
1,734th place
1,698th place
1vub.be
low place
low place
1g-ba.de
low place
1,618th place
1cochrane.org
7,609th place
5,262nd place
1clinicaltrials.gov
5,225th place
2,461st place
1slcmsr.net
low place
low place
1teva.de
low place
low place
1mylan-dura-pro.de
low place
low place
1dkms.de
low place
low place
1youtube.com
9th place
9th place

IABotmemento.invalid

  • Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data (Memento des Originals vom 22. September 2020 im Internet Archive)  Info: Der Archivlink wurde automatisch eingesetzt und noch nicht geprüft. Bitte prüfe Original- und Archivlink gemäß Anleitung und entferne dann diesen Hinweis.@1@2Vorlage:Webachiv/IABot/onlinelibrary.ectrims-congress.eu, ECTRIMS Kongress, Stockholm September 2019, abgerufen am 12. Februar 2020

aerzteblatt.de

aerztezeitung.de

akdae.de

amsel.de

atlasofms.org

awmf.org

biomedcentral.com

jneuroinflammation.biomedcentral.com

  • S. Jarius, F. B. König, I. Metz, K. Ruprecht, F. Paul, W. Brück, B. Wildemann: Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. In: J Neuroinflammation. 14. Jahrgang, S. 171, doi:10.1186/s12974-017-0929-z, PMID 28851393 (biomedcentral.com).

clinicaltrials.gov

cochrane.org

core.ac.uk

  • Maurizio Falso, Eleonora Cattaneo, Elisa Foglia, Marco Zucchini, Franco Zucchini: How does a Personalized Rehabilitative Model influence the Functional Response of Different Ankle Foot Orthoses in a Cohort of Patients Affected by Neurological Gait Pattern? Hrsg.: Journal of Novel Physiotherapy and Rehabilitation. Band 1, 2017, ISSN 2573-6264, S. 072–092 (core.ac.uk).

deutsche-apotheker-zeitung.de

dgn.org

dkms.de

dmsg.de

doi.org

ectrims-congress.eu

onlinelibrary.ectrims-congress.eu

  • Updated safety of cladribine tablets in the treatment of patients with multiple sclerosis: Integrated safety analysis and post-approval data (Memento des Originals vom 22. September 2020 im Internet Archive)  Info: Der Archivlink wurde automatisch eingesetzt und noch nicht geprüft. Bitte prüfe Original- und Archivlink gemäß Anleitung und entferne dann diesen Hinweis.@1@2Vorlage:Webachiv/IABot/onlinelibrary.ectrims-congress.eu, ECTRIMS Kongress, Stockholm September 2019, abgerufen am 12. Februar 2020

elsevier.com

linkinghub.elsevier.com

  • S. Madeh Piryonesi, Sorour Rostampour, S. Abdurrahman Piryonesi: Predicting falls and injuries in people with multiple sclerosis using machine learning algorithms. In: Multiple Sclerosis and Related Disorders. Band 49, Nr. 4, 1. Januar 2021, S. 102740, doi:10.1016/j.msard.2021.102740 (Online [abgerufen am 2. Februar 2021]).
  • Alan J. Thompson, Brenda L. Banwell, Frederik Barkhof, William M. Carroll, Timothy Coetzee: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. In: The Lancet Neurology. Band 17, Nr. 2, Februar 2018, S. 162–173, doi:10.1016/S1474-4422(17)30470-2 (elsevier.com [abgerufen am 21. Januar 2022]).

europa.eu

ema.europa.eu

ec.europa.eu

  • EPAR der EMA, (PDF; 1006 kB) Zusammenfassung der Merkmale des Arzneimittels auf der Website der EMA, abgerufen am 12. April 2022.

fda.gov

fda.gov

accessdata.fda.gov

fu-berlin.de

diss.fu-berlin.de

g-ba.de

google.cl

books.google.cl

  • D. M. Bourneville, L. Guérard: De la sclérose en plaques disséminées: nouvelle étude sur quelques points de la sclérose en plaques disséminées par Bourneville. Adrien Delahaye, Paris 1869 (books.google.cl).

google.de

books.google.de

handelsblatt.com

informa.com

scrip.pharmaintelligence.informa.com

kompetenznetz-multiplesklerose.de

medical-tribune.de

medscape.com

emedicine.medscape.com

merckgroup.com

mpg.de

multiple-sklerose.com

mylan-dura-pro.de

  • Fachinfo Clift (PDF) Website des Herstellers, abgerufen am 26. Juli 2020

nature.com

nejm.org

nih.gov

ncbi.nlm.nih.gov

  • Rajarshi Mazumder, Charles Murchison, Dennis Bourdette, Michelle Cameron: Falls in People with Multiple Sclerosis Compared with Falls in Healthy Controls. In: PLoS ONE. Band 9, Nr. 9, 25. September 2014, ISSN 1932-6203, S. e107620, doi:10.1371/journal.pone.0107620, PMID 25254633.
  • T. Hein, W. Hopfenmüller: Hochrechnung der Zahl an Multiple Sklerose erkrankten Patienten in Deutschland. In: Der Nervenarzt, Band 71, Nummer 4, April 2000, S. 288–294, PMID 10795096.
  • U. Baumhackl et al.: Prevalence of multiple sclerosis in Austria. Results of a nationwide survey. In: Neuroepidemiolog, Band 21, Nummer 5, September–Oktober 2002, S. 226–234, doi:10.1159/000065640. PMID 12207150.
  • S. Beer, J. Kesselring: High prevalence of multiple sclerosis in Switzerland. In: Neuroepidemiology. Band 13, Nummer 1–2, 1994, S. 14–18, PMID 8190201.
  • T Chitnis et al.: Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. In: Multiple Sclerosis. Band 15, Nr. 5, 2009, S. 627–631, doi:10.1177/1352458508101933, PMID 19299440.
  • Janko Samardzic, John N. van den Anker, Sasa Peric, Dejan Stevanovic, Ivan Zaletel: Multiple Sclerosis in Pediatrics: Current Concepts and Treatment Options. In: Neurology and Therapy. Band 5, Nr. 2, 1. Dezember 2016, S. 131–143, doi:10.1007/s40120-016-0052-6, PMID 27640189, PMC 5130919 (freier Volltext).
  • S. Poser, W. Poser, G. Schlaf, W. Firnhaber, K. Lauer, M. Wolter, P. Evers: Prognostic indicators in multiple sclerosis. In: Acta neurologica Scandinavica. Band 74, Nummer 5, November 1986, S. 387–392, PMID 3825497.
  • B. J. Hurwitz: Analysis of current multiple sclerosis registries. In: Neurology. Band 76, Nummer 1, Supplement 1, Januar 2011, S. S7–13, doi:10.1212/WNL.0b013e31820502f6. PMID 21205683. (Übersichtsarbeit).
  • H. Brønnum-Hansen, N. Koch-Henriksen, E. Stenager: Trends in survival and cause of death in Danish patients with multiple sclerosis. In: Brain. Band 127, Nummer 4, April 2004, S. 844–850, doi:10.1093/brain/awh104. PMID 14960501.
  • W. Hu, C. F. Lucchinetti: The pathological spectrum of CNS inflammatory demyelinating diseases. In: Seminars in Immunopathology. Band 31, Nummer 4, November 2009, S. 439–453, doi:10.1007/s00281-009-0178-z. PMID 19779719. (Übersichtsarbeit).
  • C. R. Gale, C. N. Martyn: Migrant studies in multiple sclerosis. In: Progress in neurobiology, Band 47, Nummer 4–5, November–Dezember 1995, S. 425–448; PMID 8966212 (Übersichtsarbeit).
  • H. Lassmann, W. Brück, C. Lucchinetti: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. In: Trends in Molecular Medicine, Band 7, Nummer 3, März 2001, S. 115–121; PMID 11286782 (Übersichtsarbeit).
  • S. Jarius, F. B. König, I. Metz, K. Ruprecht, F. Paul, W. Brück, B. Wildemann: Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. In: J Neuroinflammation. 14. Jahrgang, S. 171, doi:10.1186/s12974-017-0929-z, PMID 28851393 (biomedcentral.com).
  • S. Jarius, I. Metz, F. B. König, K. Ruprecht, M. Reindl, F. Paul, W. Brück, B. Wildemann B: Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. In: Mult Scler. 22. Jahrgang, Nr. 12, S. 1541–1549, doi:10.1186/s12974-017-0929-z, PMID 26869529 (sagepub.com).
  • M. Spadaro, L. A. Gerdes, M. C. Mayer, B. Ertl-Wagner, S. Laurent, M. Krumbholz, C. Breithaupt, T. Högen, A. Straube, A. Giese, R. Hohlfeld, H. Lassmann, E. Meinl, T. Kümpfel.: Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. In: Ann Clin Transl Neurol. 2. Jahrgang, S. 295–301, PMID 25815356.
  • F. B. König, B. Wildemann, S. Nessler, D. Zhou, B. Hemmer, I. Metz, H. P. Hartung, B. C. Kieseier, W. Brück: Persistence of immunopathological and radiological traits in multiple sclerosis. In: Arch Neurol. 65. Jahrgang, Nr. 11, S. 1527–1532, doi:10.1001/archneur.65.11.1527, PMID 19001173.
  • P. A. Brex et al.: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. In: The New England Journal of Medicine, Band 346, Nr. 3, Januar 2002, S. 158–164; doi:10.1056/NEJMoa011341. PMID 11796849.
  • N. Evangelou et al.: Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions. In: Brain: a journal of neurology, Band 128, Teil 1, Januar 2005, S. 29–34; doi:10.1093/brain/awh323. PMID 15548559.
  • A. Kutzelnigg et al.: Cortical demyelination and diffuse white matter injury in multiple sclerosis. In: Brain: a journal of neurology, Band 128, Nummer 11, November 2005, S. 2705–2712; doi:10.1093/brain/awh641. PMID 16230320.
  • A. Ascherio: Environmental factors in multiple sclerosis. In: Expert review of neurotherapeutics. Band 13, Nummer 12, Supplement, Dezember 2013, S. 3–9, doi:10.1586/14737175.2013.865866. PMID 24289836. (Review).
  • S. G. Gregory et al.: Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. In: Nature Genetics. Band 39, Nummer 9, September 2007, S. 1083–1091, doi:10.1038/ng2103. PMID 17660817.
  • F. Lundmark et al.: Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. In: Nature genetics. Band 39, Nummer 9, September 2007, S. 1108–1113, doi:10.1038/ng2106. PMID 17660816.
  • M. G. Marrosu: Susceptibility to multiple sclerosis: the role of interleukin genes. In: Lancet neurology. Band 6, Nummer 10, Oktober 2007, S. 846–847, doi:10.1016/S1474-4422(07)70228-4. PMID 17884670.
  • S. Sawcer: The complex genetics of multiple sclerosis: pitfalls and prospects. In: Brain. Band 131, Pt 12, Dezember 2008, S. 3118–3131, doi:10.1093/brain/awn081. PMID 18490360. PMC 2639203 (freier Volltext). (Übersichtsarbeit).
  • A. P. Gregory et al.: TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. In: Nature. Band 488, Nummer 7412, August 2012, S. 508–511, doi:10.1038/nature11307. PMID 22801493.
  • N. A. Patsopoulos et al.: Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. In: PLoS genetics. Band 9, Nummer 11, November 2013, S. e1003926, doi:10.1371/journal.pgen.1003926. PMID 24278027. PMC 3836799 (freier Volltext).
  • The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. In: Nature. Band 476, Nummer 7359, August 2011, S. 214–219, doi:10.1038/nature10251. PMID 21833088. PMC 3182531 (freier Volltext).
  • Jian Wang et al.: HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. In: Cell. Band 183, Nr. 5, 1. November 2020, S. 1264–1281.e20, doi:10.1016/j.cell.2020.09.054, PMID 33091337.
  • R. Srivastava et al.: Potassium channel KIR4.1 as an immune target in multiple sclerosis. In: The New England journal of medicine. Band 367, Nummer 2, Juli 2012, S. 115–123, doi:10.1056/NEJMoa1110740. PMID 22784115.
  • R. Schneider: Autoantibodies to Potassium Channel KIR4.1 in Multiple Sclerosis. In: Frontiers in neurology. Band 4, 2013, S. 125, doi:10.3389/fneur.2013.00125. PMID 24032025. PMC 3759297 (freier Volltext).
  • M. Alter et al.: Multiple sclerosis frequency in Israel’s diverse populations. In: Neurology. Band 66, Nummer 7, April 2006, S. 1061–1066, doi:10.1212/01.wnl.0000204194.47925.0d. PMID 16606919.
  • D. M. Williamson et al.: Prevalence of multiple sclerosis in 19 Texas counties, 1998–2000. In: Journal of environmental health. Band 69, Nummer 10, Juni 2007, S. 41–45, PMID 17583295.
  • G. C. Ebers et al.: Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. In: Annals of Neurology. Band 48, Nummer 6, Dezember 2000, S. 927–931, PMID 11117550.
  • N. P. Robertson et al.: Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. In: Brain: a journal of neurology. Band 119 ( Pt 2), April 1996, S. 449–455, PMID 8800940. doi:10.1093/brain/119.2.449.
  • S. E. Baranzini et al.: Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. In: Nature. Band 464, Nummer 7293, April 2010, S. 1351–1356, doi:10.1038/nature08990. PMID 20428171. PMC 2862593 (freier Volltext).
  • A. Katsnelson: Twin study surveys genome for cause of multiple sclerosis. In: Nature. Band 464, Nummer 7293, April 2010, S. 1259, doi:10.1038/4641259a. PMID 20428135. (Kommentar)
  • D. A. Dyment et al.: Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. In: Journal of neurology, neurosurgery, and psychiatry. Band 77, Nummer 2, Februar 2006, S. 258–259, doi:10.1136/jnnp.2005.063008. PMID 16421134. PMC 2077589 (freier Volltext).
  • B. Banwell et al.: Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. In: Lancet neurology. Band 6, Nummer 9, September 2007, S. 773–781, doi:10.1016/S1474-4422(07)70196-5. PMID 17689148.
  • S. Alotaibi et al.: Epstein-Barr virus in pediatric multiple sclerosis. In: JAMA. Band 291, Nummer 15, April 2004, S. 1875–1879, doi:10.1001/jama.291.15.1875. PMID 15100207.
  • J. F. Kurtzke et al.: Multiple sclerosis in the Faroe Islands. 5. The occurrence of the fourth epidemic as validation of transmission. In: Acta neurologica Scandinavica. Band 88, Nummer 3, September 1993, S. 161–173, PMID 8256551.
  • J. F. Kurtzke, K. Hyllested: Multiple sclerosis in the Faroe Islands: I. Clinical and epidemiological features. In: Annals of neurology. Band 5, Nummer 1, Januar 1979, S. 6–21, doi:10.1002/ana.410050104. PMID 371519.
  • Poser CM, Hibberd PL, Benedikz J, Gudmundsson G.: Analysis of the 'epidemic' of multiple sclerosis in the Faroe Islands. I. Clinical and epidemiological aspects. In: Neuroepidemiology. 1988;7(4):168-80. doi:10.1159/000110152. PMID 3194042.
  • Poser CM, Hibberd PL.: Analysis of the 'epidemic' of multiple sclerosis in the Faroe Islands. II. Biostatistical aspects. In: Neuroepidemiology. 1988;7(4):181-9. doi:10.1159/000110153. PMID 3194043.
  • Kjetil Bjornevik et al.: Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. In: Science. 21. Januar 2022, doi:10.1126/science.abj8222, PMID 35025605.
  • Kjetil Bjornevik et al.: Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. In: Science. 21. Januar 2022, doi:10.1126/science.abj8222, PMID 35025605.
  • A. L. Ponsonby et al.: Exposure to infant siblings during early life and risk of multiple sclerosis. In: JAMA. Band 293, Nummer 4, Januar 2005, S. 463–469, doi:10.1001/jama.293.4.463. PMID 15671431.
  • I. A. van der Mei et al.: Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. In: BMJ. Band 327, Nummer 7410, August 2003, S. 316, doi:10.1136/bmj.327.7410.316. PMID 12907484. PMC 169645 (freier Volltext).
  • N. Kromann, A. Green: Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950–1974. In: Acta medica Scandinavica. Band 208, Nummer 5, 1980, S. 401–406, PMID 7457208.
  • B. Deutch et al.: Traditional and modern Greenlandic food – dietary composition, nutrients and contaminants. In: Science of the Total Environment. Band 384, Nummer 1–3, Oktober 2007, S. 106–119, doi:10.1016/j.scitotenv.2007.05.042. PMID 17629548.
  • Kassandra L. Munger et al.: Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. In: Journal of Neurology. Band 258, Nr. 3, März 2011, S. 479–485, doi:10.1007/s00415-010-5783-1, PMID 20945071, PMC 3077931 (freier Volltext).
  • M. Y. Hachim, N. M. Elemam, A. A. Maghazachi: The Beneficial and Debilitating Effects of Environmental and Microbial Toxins, Drugs, Organic Solvents and Heavy Metals on the Onset and Progression of Multiple Sclerosis. In: Toxins. Band 11, Nr. 3, März 2019, doi:10.3390/toxins11030147, PMID 30841532, PMC 6468554 (freier Volltext).
  • Julia Feige et al.: Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. In: Nutrients. Band 12, Nr. 3, 16. März 2020, doi:10.3390/nu12030783, PMID 32188044, PMC 7146466 (freier Volltext).
  • K. K. Aminzadeh, M. Etminan: Dental amalgam and multiple sclerosis: a systematic review and meta-analysis. In: Journal of public health dentistry. Band 67, Nummer 1, 2007, S. 64–66, PMID 17436982. (Metaanalyse).
  • C. H. Hawkes: Smoking is a risk factor for multiple sclerosis: a metanalysis. In: Multiple sclerosis. Band 13, Nummer 5, Juni 2007, S. 610–615, doi:10.1177/1352458506073501. PMID 17548439.
  • T. Riise, M. W. Nortvedt, A. Ascherio: Smoking is a risk factor for multiple sclerosis. In: Neurology. Band 61, Nummer 8, Oktober 2003, S. 1122–1124, PMID 14581676.
  • F. di Pauli et al.: Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. In: Multiple sclerosis. Band 14, Nummer 8, September 2008, S. 1026–1030, doi:10.1177/1352458508093679. PMID 18632775.
  • P. Sundström, L. Nyström: Smoking worsens the prognosis in multiple sclerosis. In: Multiple sclerosis. Band 14, Nummer 8, September 2008, S. 1031–1035, doi:10.1177/1352458508093615. PMID 18632778.
  • Alice Grizzel Willison et al.: SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review. In: JAMA neurology. Band 81, Nr. 2, 1. Februar 2024, S. 179–186, doi:10.1001/jamaneurol.2023.5208, PMID 38227318 (englisch).
  • M. A. Hernán et al.: Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. In: Neurology. Band 63, Nummer 5, September 2004, S. 838–842, PMID 15365133.
  • Y. Mikaeloff et al.: Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. In: Archives of pediatrics & adolescent medicine. Band 161, Nummer 12, Dezember 2007, S. 1176–1182, doi:10.1001/archpedi.161.12.1176. PMID 18056563.
  • F. DeStefano et al.: Vaccinations and risk of central nervous system demyelinating diseases in adults. In: Archives of Neurology Band 60, Nummer 4, April 2003, S. 504–509, doi:10.1001/archneur.60.4.504. PMID 12707063.
  • Y. Mikaeloff et al.: Hepatitis B vaccine and risk of relapse after a first childhood episode of CNS inflammatory demyelination. In: Brain. Band 130, Pt 4 April 2007, S. 1105–1110, doi:10.1093/brain/awl368. PMID 17276994.
  • F. Zipp, J. G. Weil, K. M. Einhäupl: No increase in demyelinating diseases after hepatitis B vaccination. In: Nature medicine Band 5, Nummer 9, September 1999, S. 964–965, doi:10.1038/12376. PMID 10470051.
  • Julia Stowe et al.: Do Vaccines Trigger Neurological Diseases? Epidemiological Evaluation of Vaccination and Neurological Diseases Using Examples of Multiple Sclerosis, Guillain–Barré Syndrome and Narcolepsy. In: CNS Drugs. Band 34, Nr. 1, 1. Januar 2020, S. 1–8, doi:10.1007/s40263-019-00670-y, PMID 31576507, PMC 7224038 (freier Volltext).
  • Carlo Di Pietrantonj et al.: Vaccines for measles, mumps, rubella, and varicella in children. In: The Cochrane Database of Systematic Reviews. Band 4, 20. April 2020, S. CD004407, doi:10.1002/14651858.CD004407.pub4, PMID 32309885, PMC 7169657 (freier Volltext).
  • F. Schelling: Damaging venous reflux into the skull or spine: relevance to multiple sclerosis. In: Medical Hypotheses. Band 21, Nummer 2, Oktober 1986, S. 141–148, PMID 3641027.
  • P. Zamboni et al.: Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. In: Journal of neurology, neurosurgery, and psychiatry. Band 80, Nummer 4, April 2009, S. 392–399, doi:10.1136/jnnp.2008.157164. PMID 19060024. PMC 2647682 (freier Volltext).
  • M. Simka: Blood brain barrier compromise with endothelial inflammation may lead to autoimmune loss of myelin during multiple sclerosis. In: Current neurovascular research. Band 6, Nummer 2, Mai 2009, S. 132–139, PMID 19442163. (Übersichtsarbeit).
  • P. Sundström et al.: Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study. In: Annals of neurology. Band 68, Nummer 2, August 2010, S. 255–259, doi:10.1002/ana.22132. PMID 20695018.
  • F. Doepp et al.: No cerebrocervical venous congestion in patients with multiple sclerosis. In: Annals of neurology. Band 68, Nummer 2, August 2010, S. 173–183, doi:10.1002/ana.22085. PMID 20695010.
  • B. A. Bagert, E. Marder, O. Stüve: Chronic cerebrospinal venous insufficiency and multiple sclerosis. In: Archives of neurology. Band 68, Nummer 11, November 2011, S. 1379–1384, doi:10.1001/archneurol.2011.179. PMID 21747006. (Übersichtsarbeit).
  • A. L. Traboulsee et al.: Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. In: The Lancet. 2013 Oct 8. pii: S0140-6736(13)61747-X doi:10.1016/S0140-6736(13)61747-X, PMID 24119384.
  • H. Lassmann: Experimental models of multiple sclerosis. In: Revue neurologique. Band 163, Nummer 6–7, Juni 2007, S. 651–655, PMID 17607184. (Übersichtsarbeit).
  • Ins Deutsche übersetzt nach W. I. McDonald: Physicians, subsequence and consequence. In: Journal of Neurology, Neurosurgery, and Psychiatry. Band 67, Nummer 3, September 1999, S. 282–289, PMID 10449547. PMC 1736520 (freier Volltext).
  • MacKenzie: A practical treatise on diseases of the eye. Longman, London 1840; zitiert nach W. I. McDonald: Physicians, subsequence and consequence. In: Journal of neurology, neurosurgery, and psychiatry. Band 67, Nummer 3, September 1999, S. 282–289, PMID 10449547. PMC 1736520 (freier Volltext).
  • C. Aring: Observations on multiple sclerosis and conversion hysteria. In: Brain: A Journal of Neurology. Band 88, Nr. 4, November 1965, S. 663–674, PMID 5856073.
  • F. D. Lublin, S. C. Reingold: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. In: Neurology. Band 46, Nummer 4, April 1996, S. 907–911, PMID 8780061.
  • B. G. Weinshenker et al.: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. In: Brain. Band 112, Februar 1989, S. 133–146, PMID 2917275.
  • D. Buljevac et al.: Prospective study on the relationship between infections and multiple sclerosis exacerbations. In: Brain. Band 125, Pt 5, Mai 2002, S. 952–960, PMID 11960885.
  • C. Confavreux: Infections and the risk of relapse in multiple sclerosis. In: Brain. Band 125, Pt 5, Mai 2002, S. 933–934, PMID 11960883.
  • S. Vukusic et al., The Pregnancy In Multiple Sclerosis Group: Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. In: Brain. Band 127, Pt 6, Juni 2004, S. 1353–1360, doi:10.1093/brain/awh152. PMID 15130950.
  • D. S. Goodin et al.: The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. In: Neurology. Band 52, Nummer 9, Juni 1999, S. 1737–1745, PMID 10371517.
  • D. C. Mohr et al..: Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. In: BMJ. Band 328, Nummer 7442, März 2004, S. 731, doi:10.1136/bmj.38041.724421.55. PMID 15033880. PMC 381319 (freier Volltext). (Übersichtsarbeit).
  • A. Apel et al.: In: Fortschritte der Neurologie-Psychiatrie. Band 74, Nummer 10, Oktober 2006, S. 567–574, doi:10.1055/s-2005-919090. PMID 16586258. (Übersichtsarbeit).
  • A. Petzold, Clare L. Fraser, Mathias Abegg et al.: Diagnosis and Classification of Optic Neuritis. In: The Lancet Neurology. Band 21, Nr. 12, September 2022, S. 1120–1134, doi:10.1016/S1474-4422(22)00200-9, PMID 36179757 (Deutschen Übersetzung [PDF; abgerufen am 10. April 2024]).
  • J. M. Dargin, R. A. Lowenstein: The painful eye. In: Emergency medicine clinics of North America. Band 26, Nummer 1, Februar 2008, S. 199–216, viii, doi:10.1016/j.emc.2007.10.001. PMID 18249263. (Übersichtsarbeit).
  • C. Solaro et al.: The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. In: Neurology. Band 63, Nummer 5, September 2004, S. 919–921, PMID 15365151.
  • Caspar E. P. van Munster, Bernard M. J. Uitdehaag: Outcome Measures in Clinical Trials for Multiple Sclerosis. In: CNS Drugs. Band 31, Nr. 3, März 2017, ISSN 1172-7047, S. 217–236, doi:10.1007/s40263-017-0412-5, PMID 28185158.
  • W. I. McDonald et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. In: Annals of neurology. Band 50, Nummer 1, Juli 2001, S. 121–127, PMID 11456302.
  • Polman et al.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria“. In: Annals of neurology. Band 58, Nummer 6, Dezember 2005, S. 840–846, doi:10.1002/ana.20703. PMID 16283615. (Übersichtsarbeit).
  • Polman et al.: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. In: Annals of neurology. Band 69, Nummer 2, Februar 2011, S. 292–302, doi:10.1002/ana.22366. PMID 21387374. PMC 3084507 (freier Volltext).
  • Giovannoni et al.: Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. In: Journal of neurology. Band 248, Nummer 6, Juni 2001, S. 487–495, PMID 11499639.
  • Berger et al.: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. In: The New England Journal of Medicine. Band 349, Nummer 2, Juli 2003, S. 139–145, doi:10.1056/NEJMoa022328. PMID 12853586.
  • Kuhle et al.: Lack of association between antimyelin antibodies and progression to multiple sclerosis. In: The New England Journal of Medicine. Band 356, Nummer 4, Januar 2007, S. 371–378, doi:10.1056/NEJMoa063602. PMID 17251533.
  • H. Link, Y. M. Huang: Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. In: Journal of neuroimmunology. Band 180, Nummer 1–2, November 2006, S. 17–28, doi:10.1016/j.jneuroim.2006.07.006. PMID 16945427. (Übersichtsarbeit).
  • H. Reiber, S. Ungefehr, C. Jacobi: The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. In: Multiple sclerosis. Band 4, Nummer 3, Juni 1998, S. 111–117, PMID 9762657.
  • S. Jarius, P. Eichhorn, D. Franciotta, H.F. Petereit, G. Akman-Demir, M. Wick, B. Wildemann. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. In: J Neurol., 2016, doi:10.1007/s00415-016-8360-4, PMID 28005176
  • L. A. Rolak, J. O. Fleming: The differential diagnosis of multiple sclerosis. In: The neurologist. Band 13, Nummer 2, März 2007, S. 57–72, doi:10.1097/01.nrl.0000254705.39956.34. PMID 17351525. (Übersichtsarbeit).
  • B. G. Weinshenker et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. In: Annals of neurology. Band 46, Nummer 6, Dezember 1999, S. 878–886, PMID 10589540.
  • D. M. Sutton et al.: Complications of plasma exchange. In: Transfusion. Band 29, Nummer 2, Februar 1989, S. 124–127, PMID 2919422.
  • M. H. Mokrzycki, A. A. Kaplan: Therapeutic plasma exchange: complications and management. In: American journal of kidney diseases. Band 23, Nummer 6, Juni 1994, S. 817–827, PMID 8203364.
  • Gregoriadis et al. Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion. Expert Opin Pharmacother. 2016 Oct;17(15):2085-95; doi:10.1080/14656566.2016.1232712. PMID 27594523.
  • H. L. Weiner et al. Immunosuppressive treatment in multiple sclerosis. J Neurol Sci. 2004 Aug 15;223(1):1-11. doi:10.1016/j.jns.2004.04.013 PMID 15261554.
  • Oh and O’Connor. Established disease-modifying treatments in relapsing-remitting multiple sclerosis. 2015 Jun;28(3):220-9. doi:10.1097/WCO.0000000000000202. PMID 25923124.
  • Penn et Starzl. Malignant tumors arising de novo in immunosuppressed organ transplant recipients. 1972 Oct;14(4):407-17. PMC 3006181 (freier Volltext). PMID 4345337.
  • Ghezzi et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. 2013 Jan;260(1):327-9. doi:10.1007/s00415-012-6744-7 – PMID 23161460.
  • Filippini et al.: Interferons in relapsing remitting multiple sclerosis: a systematic review. In: Lancet. Band 361, Nummer 9357, Februar 2003, S. 545–552, doi:10.1016/S0140-6736(03)12512-3. PMID 12598138. (Metaanalyse).
  • L. Munari, R. Lovati, A. Boiko: Therapy with glatiramer acetate for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 1, 2004, S. CD004678, doi:10.1002/14651858.CD004678. PMID 14974077. (Metaanalyse).
  • I. Casetta, G. Iuliano, G. Filippini: Azathioprine for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 4, 2007, S. CD003982, doi:10.1002/14651858.CD003982.pub2. PMID 17943809. (Metaanalyse).
  • O. Gray, G. V. McDonnell, R. B. Forbes: Intravenous immunoglobulins for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 4, 2003, S. CD002936, doi:10.1002/14651858.CD002936. PMID 14583956. (Metaanalyse).
  • J. A. Cohen et al.: Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. In: The New England Journal of Medicine. Band 362, Nummer 5, Februar 2010, S. 402–415, doi:10.1056/NEJMoa0907839. PMID 20089954.
  • L. Kappos et al.: A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. In: The New England Journal of Medicine. Band 362, Nummer 5, Februar 2010, S. 387–401, doi:10.1056/NEJMoa0909494. PMID 20089952.
  • Polman et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. In: The New England Journal of Medicine. Band 354, Nummer 9, März 2006, S. 899–910, doi:10.1056/NEJMoa044397. PMID 16510744.
  • Martinelli Boneschi et al.: Mitoxantrone for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 4, 2005, S. CD002127, doi:10.1002/14651858.CD002127.pub2. PMID 16235298. (Metaanalyse).
  • La Mantia et al.: Cyclophosphamide for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 1, 2007, S. CD002819, doi:10.1002/14651858.CD002819.pub2. PMID 17253481. (Metaanalyse).
  • De Jong et al.: Confusing Cochrane reviews on treatment in multiple sclerosis. In: Lancet neurology. Band 4, Nummer 6, Juni 2005, S. 330–331, doi:10.1016/S1474-4422(05)70081-8. PMID 15907736. (Kommentar)
  • M. B. Rietberg et al.: Exercise therapy for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 1, 2005, S. CD003980, doi:10.1002/14651858.CD003980.pub2. PMID 15674920. (Meta-Analyse)
  • J. Kesselring, S. Beer: Symptomatic therapy and neurorehabilitation in multiple sclerosis. In: Lancet neurology. Band 4, Nummer 10, Oktober 2005, S. 643–652, doi:10.1016/S1474-4422(05)70193-9. PMID 16168933. (Übersichtsarbeit).
  • D. T. Shakespeare, M. Boggild, C. Young: Anti-spasticity agents for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 4, 2003, S. CD001332, doi:10.1002/14651858.CD001332. PMID 14583932.
  • Pöllmann et al.: Therapie von Schmerzen bei MS – eine Übersicht mit evidenzbasierten Therapieempfehlungen. In: Fortschritte der Neurologie-Psychiatrie. Band 73, Nummer 5, Mai 2005, S. 268–285, doi:10.1055/s-2004-830193. PMID 15880305. (Übersichtsarbeit).
  • V. Kalsi, C. J. Fowler: Therapy Insight: bladder dysfunction associated with multiple sclerosis. In: Nature clinical practice. Urology. Band 2, Nummer 10, Oktober 2005, S. 492–501, doi:10.1038/ncpuro0323. PMID 16474623. (Übersichtsarbeit).
  • R. M. Merson, M. I. Rolnick: Speech-language pathology and dysphagia in multiple sclerosis. In: Physical medicine and rehabilitation clinics of North America. Band 9, Nummer 3, August 1998, S. 631–641, PMID 9894114. (Übersichtsarbeit).
  • Psychological interventions for multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 1, 2006, S. CD004431, doi:10.1002/14651858.CD004431.pub2. PMID 16437487.
  • Tomassini et al.: Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. In: Journal of the neurological sciences. Band 218, Nummer 1–2, März 2004, S. 103–108, doi:10.1016/j.jns.2003.11.005. PMID 14759641.
  • Wingerchuk et al.: A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. In: Neurology. Band 64, Nummer 7, April 2005, S. 1267–1269, doi:10.1212/01.WNL.0000156803.23698.9A. PMID 15824361.
  • Rammohan et al.: Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. In: J Neurol Neurosurg Psychiatry. 2002;72, S. 179–183 PMID 11796766
  • Pucci et al.: Amantadine for fatigue in multiple sclerosis. In: Cochrane database of systematic reviews (Online). Nummer 1, 2007, S. CD002818, doi:10.1002/14651858.CD002818.pub2. PMID 17253480. (Metaanalyse).
  • Stankoff et al.: Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. In: Neurology. Band 64, Nummer 7, April 2005, S. 1139–1143, doi:10.1212/01.WNL.0000158272.27070.6A. PMID 15824337.
  • Chiara Pinarello, Julia Elmers, Hernán Inojosa, Christian Beste, Tjalf Ziemssen: Management of multiple sclerosis fatigue in the digital age: from assessment to treatment. In: Frontiers in Neuroscience. Band 17, 5. Oktober 2023, ISSN 1662-453X, S. 6, doi:10.3389/fnins.2023.1231321, PMID 37869507, PMC 10585158 (freier Volltext).
  • B. M. Hulter, P. O. Lundberg: Sexual function in women with advanced multiple sclerosis. In: Journal of neurology, neurosurgery, and psychiatry. Band 59, Nummer 1, Juli 1995, S. 83–86, PMID 7608715. PMC 1073606 (freier Volltext).
  • M. Zorzon et al.: Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. In: Multiple sclerosis. Band 5, Nummer 6, Dezember 1999, S. 418–427, PMID 10618699.
  • D. Borello-France et al.: Bladder and sexual function among women with multiple sclerosis. In: Multiple sclerosis. Band 10, Nummer 4, August 2004, S. 455–461, PMID 15327046.
  • R. DasGupta, C. J. Fowler: Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. In: Current opinion in neurology. Band 15, Nummer 3, Juni 2002, S. 271–278, PMID 12045724. (Review).
  • Natalie E. Parks et al.: Dietary interventions for multiple sclerosis-related outcomes. In: The Cochrane Database of Systematic Reviews. Band 5, 19. Mai 2020, S. CD004192, doi:10.1002/14651858.CD004192.pub4, PMID 32428983, PMC 7388136 (freier Volltext).
  • Apel et al.: Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis. In: Journal of neurology. Band 253, Nummer 10, Oktober 2006, S. 1331–1336, doi:10.1007/s00415-006-0217-9. PMID 16786211.
  • Pucci et al.: Why physicians need to look more closely at the use of complementary and alternative medicine by multiple sclerosis patients. In: European journal of neurology. Band 11, Nummer 4, April 2004, S. 263–267, doi:10.1046/j.1468-1331.2003.00758.x. PMID 15061828.
  • S. Schwarz et al.: Alternative und komplementäre Therapien der Multiplen Sklerose. In: Fortschritte der Neurologie-Psychiatrie. Band 73, Nummer 8, August 2005, S. 451–462, doi:10.1055/s-2004-830248. PMID 16052439. (Übersichtsarbeit)
  • B. A. Cohen, P. Rieckmann: Emerging oral therapies for multiple sclerosis. In: International journal of clinical practice. Band 61, Nummer 11, November 2007, S. 1922–1930, doi:10.1111/j.1742-1241.2007.01561..x. PMID 17784852. (Review).
  • P. A. Muraro, B. Bielekova: Emerging therapies for multiple sclerosis. In: Neurotherapeutics. Band 4, Nummer 4, Oktober 2007, S. 676–692, doi:10.1016/j.nurt.2007.07.003. PMID 17920549. (Übersichtsarbeit über aktuelle Forschungsschwerpunkte)
  • Christoph Kleinschnitz et al.: Multiple sclerosis therapy: an update on recently finished trials. In: Journal of neurology. Band 254, Nummer 11, November 2007, S. 1473–1490, doi:10.1007/s00415-007-0684-7. PMID 18004638. (Review). (Übersichtsarbeit über aktuelle Forschungsschwerpunkte)
  • Blanco et al.: Autologous haematopoietic-stem-cell transplantation for multiple sclerosis. In: Lancet neurology. Band 4, Nummer 1, Januar 2005, S. 54–63, doi:10.1016/S1474-4422(04)00966-4. PMID 15620857. (Übersichtsarbeit zur autologen Stammzelltransplantation)
  • Gladstone et al.: High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. In: Archives of neurology. Band 63, Nummer 10, Oktober 2006, S. 1388–1393, doi:10.1001/archneur.63.10.noc60076. PMID 16908728.
  • H. L. Atkins et al.: Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 Trial. Lancet. 8. Juni 2016, pii: S0140-6736(16)30169-6. PMID 27291994, doi:10.1016/S0140-6736(16)30169-6.
  • Vana et al.: Platelet-derived growth factor promotes repair of chronically demyelinated white matter. In: Journal of Neuropathology & Experimental Neurology, Band 66, Nummer 11, November 2007, S. 975–988, doi:10.1097/NEN.0b013e3181587d46. PMID 17984680. PMC 2788485 (freier Volltext).
  • Nait-Oumesmar et al.: Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. In: Proceedings of the National Academy of Sciences. Band 104, Nummer 11, März 2007, S. 4694–4699, doi:10.1073/pnas.0606835104. PMID 17360586. PMC 3025281 (freier Volltext).
  • Pittock et al.: Change in MS-related disability in a population-based cohort: a 10-year follow-up study. In: Neurology. Band 62, Nummer 1, Januar 2004, S. 51–59, PMID 14718697.
  • Daumer et al.: Prognosis of the individual course of disease–steps in developing a decision support tool for Multiple Sclerosis. In: BMC medical informatics and decision making. Band 7, 2007, S. 11, doi:10.1186/1472-6947-7-11. PMID 17488517. PMC 1884137 (freier Volltext). Dort vorgestelltes Web-basiertes Programm zur Bestimmung des Risikoprofils.

pharmaphorum.com

pharmazeutische-zeitung.de

redirecter.toolforge.org

reuters.com

rki.de

sagepub.com

journals.sagepub.com

  • S. Jarius, I. Metz, F. B. König, K. Ruprecht, M. Reindl, F. Paul, W. Brück, B. Wildemann B: Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. In: Mult Scler. 22. Jahrgang, Nr. 12, S. 1541–1549, doi:10.1186/s12974-017-0929-z, PMID 26869529 (sagepub.com).
  • Camela Leone, Deborah Severijns et al.: Prevalence of Walking-Related Motor Fatigue in Persons With Multiple Sclerosis. In: Neurorehabilitation and Neural Repair. 4. Auflage. Nr. 30. Sage Journals, 2015, S. 373–383 (sagepub.com).

sanofi.com

sciencedirect.com

  • Davide Cattaneo, Carmela De Nuzzo, Marco Macalli, Ivana Pisoni, Roldano Cardini: Risks of falls in subjects with multiple sclerosis. In: Archives of Physical Medicine and Rehabilitation. Nr. 83, 2002, S. 864–867 (sciencedirect.com).

scientificamerican.com

slcmsr.net

spektrum.de

springer.com

link.springer.com

  • N. Wagner et al.: Impfen bei Immundefizienz. (PDF; 409 kB) In: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 4, 2019; abgerufen am 16. September 2020.

teva.de

ucl.ac.uk

discovery.ucl.ac.uk

uniklinik-freiburg.de

vam.ac.uk

collections.vam.ac.uk

vub.be

researchportal.vub.be

  • Eva Swinnen, Tom Deliens, Elke Dewulf, Shauni Van Overstraeten, Nina Lefeber, Johan Van Nieuwenhoven, Stephan Ilsbroukx, Eric Kerckhofs: What is the opinion of patients with multiple sclerosis and their healthcare professionals about lower limb orthoses? A qualitative study using focus group discussions. In: NeuroRehabilitation. Band 42, Nr. 1, 2018, S. 81–92 (vub.be).

web.archive.org

who.int

youtube.com

zdb-katalog.de

  • J. F. Kurtzke: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). In: Neurology. Band 33, Nr. 11, 1. November 1983, ISSN 0028-3878, S. 1444–1444, doi:10.1212/WNL.33.11.1444.
  • Rajarshi Mazumder, Charles Murchison, Dennis Bourdette, Michelle Cameron: Falls in People with Multiple Sclerosis Compared with Falls in Healthy Controls. In: PLoS ONE. Band 9, Nr. 9, 25. September 2014, ISSN 1932-6203, S. e107620, doi:10.1371/journal.pone.0107620, PMID 25254633.
  • Wallace J. Brownlee, Todd A. Hardy, Franz Fazekas, David H. Miller: Diagnosis of multiple sclerosis: progress and challenges. In: The Lancet. Band 389, Nr. 10076, April 2017, ISSN 0140-6736, S. 1336–1346, doi:10.1016/s0140-6736(16)30959-x.
  • Wallace J Brownlee, Todd A Hardy, Franz Fazekas, David H Miller: Diagnosis of multiple sclerosis: progress and challenges. In: The Lancet. Band 389, Nr. 10076, April 2017, ISSN 0140-6736, S. 1336–1346, doi:10.1016/s0140-6736(16)30959-x.
  • Rohit Bakshi: Fatigue associated with multiple sclerosis: diagnosis, impact and management. In: Multiple Sclerosis Journal. Band 9, Nr. 3, Juni 2003, ISSN 1352-4585, S. 219–227, doi:10.1191/1352458503ms904oa.
  • D. Denney, L. Sworowski, S. Lynch: Cognitive impairment in three subtypes of multiple sclerosis. In: Archives of Clinical Neuropsychology. Band 20, Nr. 8, Dezember 2005, ISSN 0887-6177, S. 967–981, doi:10.1016/j.acn.2005.04.012.
  • L. M. J. De Sonneville, J. B. Boringa, I. E. W. Reuling, R. H. C. Lazeron, H. J. Adèr: Information processing characteristics in subtypes of multiple sclerosis. In: Neuropsychologia. Band 40, Nr. 11, Januar 2002, ISSN 0028-3932, S. 1751–1765, doi:10.1016/s0028-3932(02)00041-6.
  • Rosa E. Boeschoten, Annemarie M. J. Braamse, Aartjan T. F. Beekman, Pim Cuijpers, Patricia van Oppen: Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. In: Journal of the Neurological Sciences. Band 372, Januar 2017, ISSN 0022-510X, S. 331–341, doi:10.1016/j.jns.2016.11.067.
  • Lauren B Krupp: Fatigue in Multiple Sclerosis. In: CNS Drugs. Band 17, Nr. 4, 2003, ISSN 1172-7047, S. 225–234, doi:10.2165/00023210-200317040-00002.
  • I.-K. Penner: Evaluation of cognition and fatigue in multiple sclerosis: daily practice and future directions. In: Acta Neurologica Scandinavica. Band 134, September 2016, ISSN 0001-6314, S. 19–23, doi:10.1111/ane.12651.
  • Pasquale Calabrese, Iris Katharina Penner: Cognitive dysfunctions in multiple sclerosis – a “multiple disconnection syndrome”? In: Journal of Neurology. Band 254, S2, Mai 2007, ISSN 0340-5354, S. II18–II21, doi:10.1007/s00415-007-2006-5.
  • Caspar E. P. van Munster, Bernard M. J. Uitdehaag: Outcome Measures in Clinical Trials for Multiple Sclerosis. In: CNS Drugs. Band 31, Nr. 3, März 2017, ISSN 1172-7047, S. 217–236, doi:10.1007/s40263-017-0412-5, PMID 28185158.
  • Maurizio Falso, Eleonora Cattaneo, Elisa Foglia, Marco Zucchini, Franco Zucchini: How does a Personalized Rehabilitative Model influence the Functional Response of Different Ankle Foot Orthoses in a Cohort of Patients Affected by Neurological Gait Pattern? Hrsg.: Journal of Novel Physiotherapy and Rehabilitation. Band 1, 2017, ISSN 2573-6264, S. 072–092 (core.ac.uk).
  • Chiara Pinarello, Julia Elmers, Hernán Inojosa, Christian Beste, Tjalf Ziemssen: Management of multiple sclerosis fatigue in the digital age: from assessment to treatment. In: Frontiers in Neuroscience. Band 17, 5. Oktober 2023, ISSN 1662-453X, S. 6, doi:10.3389/fnins.2023.1231321, PMID 37869507, PMC 10585158 (freier Volltext).

zeit.de